CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:An NGS-based assay for accurate detection and quantification of immune gene expression in mouse tumor models.
An NGS-based assay for accurate detection and quantification of immune gene expression in mouse tumor models.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤微环境(TME)是一个复杂的动态系统,包含许多与肿瘤相互作用的组分,包括肿瘤浸润白细胞(TIL)、癌症相关成纤维细胞、血管及其他基质成分。它本质上影响肿瘤发展及肿瘤治疗药物的药理学,尤其是免疫肿瘤(IO)治疗。
因此,准确测量TME对于理解肿瘤免疫、识别IO治疗机制、开发预测性生物标志物,以及最终改善癌症治疗至关重要。在此,我们介绍一种基于小鼠IO NGS(NGSmIO)的检测方法,用于准确检测和定量小鼠肿瘤模型中1080个TME相关基因的mRNA表达。NGSmIO panel被证明优于常用的微阵列方法,其包含多300个相关基因,能更好地表征各种免疫细胞谱系,显示与流式细胞术的mRNA和蛋白表达相关性改善,与测序深度高10倍的RNAseq相比显示更强的mRNA表达相关性,并在测量低表达基因时表现出更高的灵敏度。
我们描述了两项研究;第一,检测MC38和Hepa 1-6肿瘤中抗PD-1:抗CD4联合治疗后干扰素-γ表达水平的药效学变化;第二,使用谱系特异性基因的转录水平表达对14种同系肿瘤中的基线TIL进行基准测试,这证明了NGSmIO panel的有效和稳健应用。
Tumor microenvironment (TME) is a complex dynamic system with many tumor-interacting components including tumor-infiltrating leukocytes (TILs), cancer associated fibroblasts, blood vessels, and other stromal constituents.
It intrinsically affects tumor development and pharmacology of oncology therapeutics, particularly immune-oncology (IO) treatments. Accurate measurement of TME is therefore of great importance for understanding the tumor immunity, identifying IO treatment mechanisms, developing predictive biomarkers, and ultimately, improving the treatment of cancer.
Here, we introduce a mouse-IO NGS-based (NGSmIO) assay for accurately detecting and quantifying the mRNA expression of 1080 TME related genes in mouse tumor models.
The NGSmIO panel was shown to be superior to the commonly used microarray approach by hosting 300 more relevant genes to better characterize various lineage of immune cells, exhibits improved mRNA and protein expression correlation to flow cytometry, shows stronger correlation with mRNA expression than RNAseq with 10x higher sequencing depth, and demonstrates higher sensitivity in measuring low-expressed genes.
We describe two studies; firstly, detecting the pharmacodynamic change of interferon-γ expression levels upon anti-PD-1: anti-CD4 combination treatment in MC38 and Hepa 1-6 tumors; and secondly, benchmarking baseline TILs in 14 syngeneic tumors using transcript level expression of lineage specific genes, which demonstrate effective and robust applications of the NGSmIO panel.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。